Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration

British Journal of Ophthalmology

Volumn 92, Issue 4, 2008, Pages 584-

  Mojica, G ^a   Hariprasad, S M ^b   Jager, R D ^b   Mieler, W F ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

CLINICAL ARTICLE; DRUG EFFECT; FOLLOW UP; HUMAN; INJECTION; INTRAOCULAR PRESSURE; LETTER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; RETROSPECTIVE STUDIES;

EID: 41849146421     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.126193     Document Type: Letter

References (1)

1. Rosenfeld PJ, Brown DM, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006;355:1419-31.